SymBio Pharmaceuticals Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 6/6
SymBio Pharmaceuticals has a total shareholder equity of ¥5.2B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥6.1B and ¥910.0M respectively.
Wichtige Informationen
0%
Verhältnis von Schulden zu Eigenkapital
JP¥0
Verschuldung
Zinsdeckungsgrad | n/a |
Bargeld | JP¥5.13b |
Eigenkapital | JP¥5.16b |
Gesamtverbindlichkeiten | JP¥910.00m |
Gesamtvermögen | JP¥6.07b |
Jüngste Berichte zur Finanzlage
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely
Sep 24Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation
Feb 09Recent updates
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely
Sep 24SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up
Aug 06Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge
Jun 11Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation
Feb 09If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%
Dec 18Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: 4582's short term assets (¥6.0B) exceed its short term liabilities (¥906.0M).
Langfristige Verbindlichkeiten: 4582's short term assets (¥6.0B) exceed its long term liabilities (¥4.0M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: 4582 is debt free.
Schulden abbauen: 4582 had no debt 5 years ago.
Bilanz
Liquiditätsreserve-Analyse
Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.
Stabile Start- und Landebahn für Bargeld: 4582 has sufficient cash runway for more than 3 years based on its current free cash flow.
Vorhersage Cash Runway: 4582 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 34.4% each year